To test the sufficiency of AURKB inhibition to limit BRAFV600E hyperproliferation in melanoma, we assessed normalized growth rate inhibition of three cultures—primary human melanocytes, an established BRAFV600E human melanoma cell line, and a short-term BRAFV600E human melanoma culture—when exposed to a pharmacologic AURKB inhibitor (Barasertib). This evidence concerns the gene AURKB and melanoma.